Brief Elevator Pitches for Startups 2018 Portfolio Class Leonhardt’s Launchpads –
as of December 5th, 2018

WARNING: These elevator pitches are brief and concise by nature. By being so brief appropriate risks are not conveyed in these short statements. These elevator pitches reflect only the most positive optimistic personal opinions of the startup founders. Full risk statements are found at the bottom, in our private placement memorandum and other locations. These risk warnings include – Our patents may not hold up or protect us. Our patents pending may not be issued. We have too little data to support any performance claims definitively at this time. Early data is uncontrolled and is not statistically significant. We are underfunded for the work we plan to do. We are understaffed for the work we plan to do. Our small staff is diverted from focused attention with other jobs and many projects. All of our advisor, employment, supplier and patent license option agreements are subject to conditions which may not be met and are often in arrears due to financial constraints. We are attempting to achieve product performance goals never reached before by other groups with substantially higher amount of resources.
  • 1.  Heart & Cardiovascular.

  • 2.  Brain.

  • 3.  Cosmetic & Personal Care.

  • 4.  Major Organ Regeneration.

  • 5.  Cancer. 


2018 Portfolio of Startups 


 Second Heart Assist, Inc. – circulatory assist pumps
 BioLeonhardt  – heart regeneration.

>  AortaCell – aorta regeneration.
>  BioPace – biological pacemaker regeneration.
>  Valvublator – heart valve regeneration.
 VibroCell CoroStim– vibrational energy to prevent clots, plaque, calcification.
 Vascustim (formerly MyoStim Peripheral)– limb blood flow improvement.
 PressureStim – bioelectric blood pressure control.


 CerebraCell – brain regeneration.

Cosmetic & Personal Care

 Stem Cell Bra – breast regeneration.
 DentaCell Accelerator – dental gum regeneration + tooth pulp storage.
 OrthodontiCell – bioelectric teeth straightening acceleration.
 SkinStim (formerly MyoStim Skin) – skin regeneration.
>  MyoStim ED ErectiStim – bioelectric erectile dysfunction treatment.
>  HairCell – hair regeneration
>  TestiStim – bioelectric testosterone management and infertility treatment.

Major Organ Regeneration 

>  EyeCell – eye regeneration.
 PancreaCell – pancreas regeneration.
>  RegenaLung – lung regeneration.
 LiverCell – liver regeneration.
>  KidneyCell – kidney regeneration.
>  EarCell – ear hearing regeneration.
 BladderCell – bladder regeneration.
 InStim – bioelectric inflammation management.
>  PolypStim – bioelectric polyp removal.
>  Wave – bioelectric endometriosis treatment.

>  OrthoStim – knee, bone and joint regeneration. 
>  BioLeonhardt Whole Body Regeneration – Whole body regeneration.

Cancer Treatment 

>  CancerCell – bioelectric cancer tumor treatment + regeneration.

Heart & Cardiovascular – 8 startups 3 at clinical stage. 

Second Heart Assist, Inc. – Developing both a temporary catheter based circulatory assist pump and a wireless powered chronic implant pump.  One competitor is on the U.S.A. market with a catheter based pump and they peaked at $21 billion valuation this year with year to year sales growth exceeding 30%.  There is no competitor yet on the market with a wireless powered chronic implant pump.   The Second Heart Assist team has completed animal studies in Boston and Ohio as well as mock loop studies at the University of Louisville and Computational Fluid Dynamics studies in Berlin, Germany.  The team has meet three times with the FDA as part of the interactive review process for an Early Feasibility Study.   The team is finishing another round of pre-clinical studies with intention to enter clinical studies in Paraguay, Australia and the USA at Ohio State University within the next 90 days.  IRB submissions have already been made.  Second Heart Assist has numerous issued patents and dozens of new patent claims pending including those covering aortic stent cage design for greater stability, vibrational harmonic resonance to prevent blood clot formations, low RPM high flow design elements intended to reduce hemolysis and mechanical breakdown risks, unique impeller shape, pulsating stent graft in upper aorta and impeller aortic stent in lower aorta in timing optimization and more.   The team expects to be in position to secure a strategic partner by spring of 2019 after clinical results from three centers.  The Second Heart Assist conforming aortic stent used on both the tip of the temporary catheter based pump and the wireless powered chronic implant is modeled after the original Leonhardt patented aortic stent graft that has world market leadership today for non-surgical repair of aortic aneurysms. 
BioLeonhardt – Developing a combination bioelectric stimulation, micro infusion pump and fifteen component composition intended to full regenerate ailing hearts.   The Leonhardt team completed their first muscle stem cell repair of an infarcted large animal heart in 1988.  Published first bioelectric regeneration paper in Circulation in 1999.  Led team that completed landmark first ever non-surgical stem cell repair of a human heart in 2001.  The BioLeonhardt technology platform represents the culmination of everything learned by more than 100 involved researchers since the 1980’s.   Small animal feasibility studies were completed at the University of Utah last year and at the team is moving on to large animal studies at Texas Heart Institute with the team of Dr. Doris Taylor and Dr. Luis Sampaio now.  In 2017 a separate independent team in Germany published a study confirming the ability of bioelectric signaling to improve cardiac function –  The team has hope to launch a first-in-man study for the combination therapy in late 2019 or 2020.  If successful the BioLeonhardt technology has the potential to cut in half the more than $30 billion annual cost of caring for heart failure patients annually.  
Aortacell – – In the 1990’s the Leonhardt team revolutionized the repair of aortic aneurysms without surgery with their patented endovascular aortic stent graft system that still holds market leadership today.  The team completed the historic landmark first ever non-surgical repair of an aortic aneurysm in Australia in 1995.  Today this same team is set to obsolete their previous market leading technology with the development of AortaCell a bioelectric and biologics combination therapy to regrow and regenerate the aorta muscular wall instead of placing an artificial implant.  The team is preparing to launch large animal studies at the University of Virginia in early 2019 with intention to move to first in man study late 2019 or 2020.  The AortaCell technology has the potential to open up a whole new market segment as well in treating smaller aneurysms that are currently left into a watch and wait program today.  AortaCell may also be used to strengthen aortic walls to improve sealing results with stent grafts in cases where they still may be used in very advanced large aortic aneurysms.  The global market for aortic aneurysm repair is forecasted to soon exceed $3.8 billion annually without factoring in the new market of earlier repair non-invasively of smaller aneurysms. 
BioPace – – Over 3 million people worldwide have an implanted electronic pacemaker with a market about to exceed $6 billion annually. The related A-Fib market is estimated to be nearly $14 billion annually. Over 400,000 deaths annually in the USA alone are attributed to electrical heart abnormalities. All healthy people function well with a natural biological pacemaker made up of living cells and healthy conduction cells within their heart. BioPace is working to develop and has patent and patent pending a pipeline of products that utilize bioelectric signaling + stem cells + growth factors + optogenetics to restore normal pacing and electrical conduction within an ailing heart. We believe restoring your own natural heart pacing function with living cells, the way it is built in the first place, is a far better alternative to getting a steel can with an electronic circuit board, battery and steel leads in your heart. BioPace is working with Electrophysiologists Dr. Alonso Moreno formerly of the University of Utah Cardiovascular Research and Training Institute, Dr. Nic Peters of Imperial Hospital London and Dr. Sergio Pinski of Cleveland Clinic Florida and we are filing multiple research grant applications as we are building and testing prototypes as well as filing new patent claims. BioPace hopes to complete animal studies in 2019 that lead to clinical studies in 2020. BioPace is dedicated to rebuilding the electrical conduction system of your own heart the same way it was built in the first place with living cells.  The intention is to regenerate your natural pacemaker instead of getting an artificial steel can and battery device. 
Valvublator  – –  Valvublator will significantly reduce the number of prosthetic heart valve implantations by decalcifying and rehabilitating existing heart valve tissue with an innovative and minimally invasive technique. The team that developed and patented the first percutaneous heart valve in the 1990’s intends to disrupt its own invention with this advanced innovation. This technology allows people to keep their own heart valve by cleaning, maintaining and regenerating their own heart valves, just as dental hygiene controls plaque formation on your teeth. The result is a healthier, longer-lasting natural heart. It is expected to have a major disruptive impact on the $20 billion prosthetic heart valve market. Led by medical device veteran Richard Henson and notable international experts in the field, the development team is creating and testing prototypes and additional patents. Valvublator hopes to complete pre-clinical studies in 2019 with intention to launch a first-in-man study in Italy with Dr. Antonio Colombo in 2020.
VibroCell Corostim – – Blood clot, calcification and plaque formation on blood contact surfaces is a leading cause of death. Thrombosis alone contributes to more than 52.8 million deaths annually according to the GBD. The CoroStim VibroCell team has developed a vibrational harmonic resonance energy technology that it believes can possibly stop blood clots, calcification and plaque from forming on both natural and artificial blood contact surfaces. Blood clots have been the Achille’s Heel of long term circulatory assist support devices and heart valves. Current Status – Patents filed. Building prototypes for testing. Seeking out research collaborators.  Working with Queensland University Brisbane, Australia and research collaborators in Pittsburgh and Utah to launch animal studies
Vascustim – – ;Over 1 million diabetic related amputations are expected this year alone. Over 23 million amputations are expected by 2030. The diabetes population is exploding rising from 108 million in 1980 to 422 million in 2014 and expected to increase by 25 to 50% more by 2030. Vascustim through collaborations has completed clinical studies in Czech Republic, Germany, Switzerland and Mexico in more than 70 patients utilizing bioelectric microcurrent stimulation and/or stem cells. Over 30 papers have been published by a variety of teams from around the world documenting the benefits of bioelectric stimulation in improving wound healing A separate study was completed independently by researchers in Czech Republic demonstrating the benefit of adding selected growth factors. We partnered with Axolotl Biologics  amniotic fluid compositions have documented dozens of cases of diabetic leg and foot wound healing and numerous independent studies have been published documenting the same.  Their processing preserves exosomes for longer length growth factor expressions.  We also developed and have patent pending bioelectric PRF platlet rich fibrin which has demonstrated incredible healing properties in multiple applications  The VascuStim approach is to combine specific bioelectric stimulation signals for stem cell homing, blood vessel growth, healing and tissue regeneration with stem cells and selected growth factors for healing diabetic foot and leg ulcers and for limb salvage. In some studies in some countries such as the USA we will utilize only bioelectric stimulation and amniotic fluid membranes to get started due to regulatory constraints. Our bench top bioelectric stimulator via our manufacturing partner in California already has FDA 510K market clearance for improving blood circulation. Amniotic fluid membranes are already marketed under the homologous exemption.  Current Status = We now are launching a worldwide paid registry clinical trial at multiple centers with plans for us getting paid for the product during the studies under category B designation reimbursement.
Pressurestim – – In the USA alone over 80 million people have high blood pressure.  1 out of every 3 Americans. Many millions also have low blood pressure problems. Pressurestim is developing a bioelectric solution to high and low blood pressure with small bioelectric stimulators the size of nickel placed in strategic locations. A clinical study has been completed in China with positive results and studies are now moving to other OUS locations. 
Cerebracell – – utilizes bioelectrics and biologics for brain regeneration.  Entering studies now at McGowan Regenerative Medicine Institute in Pittsburgh.  Team has developed a “brain saving helmet” for non-invasive reduction of brain injury following strokes and traumatic brain injuries.  The group is developing treatments for Parkinson’s, Alzheimer’s and epilepsy as well.  The Pittsburgh team previously published positive results in animal studies with their ECM matrix biologics solution. The new study combines bioelectrics with biologics to attempt to improve upon results.  A separate Stanford independent clinical study recently showed the ability to get wheelchair bound post stroke patients to get up and walk again with a single treatment with injected modified stem cells.  The CerebraCell team is working to improve upon their results.

Cosmetic & Personal Care – All 7 products at clinical stage of development 

SkinStim – – Entering clinical studies now in Los Angeles, Pittsburgh, South Africa, Austin, Texas and other locations. Face and neck skin regeneration. Product features controlled stem cell homing and tropoelastin release for increasing elasticity. Most people lose their ability to express elastin at puberty. Lack of elastin causes all tissues including skin to lose elasticity over time. SkinStim has discovered and developed a bioelectric signaling sequence the turns the elastin elasticity protein expression switch back on. The skin products market exceeds $200 billion annually. No product available so far is able to home stem cells, repair DNA, improve muscle tone, improve circulation and most important turn the elastin elasticity protein switch back on. We believe that SkinStim will be proven to stand apart and above all other skin rejuvenation therapies.
HairCell – – Launched clinical study in South Africa and about to launch in other locations. Targeting 30% hair density growth. Samumed of San Diego raised $438 million at a $12 billion valuation for their Wnt signaling technology startup that achieved 10% hair density improvement. We believe our combination of bioelectrics and biologics can do 3X better. The hair care products market exceeds $211 billion annually and the hair loss treatment segment is estimated to be over $930 million.
MyoStim ED – – Completed and published first clinical study with 85% success results over placebo (placebo had 0% success) with one signal tested. Launching new study with multiple signals, including muscle regeneration, targeting as a goal 100% success of ED recovery. The erectile dysfunction market exceeds $7 billion annually. No other product provides a cure. We believe MyoStim ED ErectiStim has the potential to nearly obsolete drugs like Viagra and Cialis that provide only temporary relief.
TestiStim – – Issued patented for bioelectric underwear for testosterone management. Pilot clinical evaluation completed with successful results. Moving to larger scale pilot studies. The testosterone boost market is estimated to be exceeding $5 billion annually and could be much larger with a safer product with less side effects based on precise dose management. The male infertility market is projected to reach $4.7 billion annually by 2025. TestiStim II is the first product designed to modulate testosterone levels with near real time monitoring and bioelectric signaling.
OrthodontiCell – – Targeting to reduce time to straighten teeth by 2/3rds and to freeze stabilized teeth straight after straightening. Market leader Align Technology peaked at $30.9 billion valuation this year and was no. 1 S&P 500 stock of 2017. They charge > $4000 and take > 18 months to straighten teeth and have no technology to keep them straight. We believe we can straighten teeth in 6 months and keep them straight. Entering clinical trials now at multiple sites. Research collaborators published positive animal study.
DentaCell – – Multiple dentistry products in development utilizing combination of bioelectrics and biologics. The dentistry products market exceeds $60 billion annually and dentists are expanding their treatment options for patients to include things like treatments for snoring not traditionally thought of as a dentistry product. The DentaCell accelerator is developing multiple innovations for multiple applications of use applying bioelectrics, biologics and holistic precision therapies.
Stem Cell Bra – – Multiple sheep studies demonstrate up to 30% increase in breast fullness volume with only one hour of wear of the Stem Cell Bra every other day for 4 weeks. Now moving to clinical studies in South Africa and other locations. It is estimated that as many as 2 billion women worldwide would choose a safer product which may be convenient to use at an affordable price to enhance their breast fullness, shape and firmness at some time in their lifetime often after giving birth to bring them back to their original shape, firmness and size.
NEW Peach – – web site under development – bioelectric vaginal rejuvenation. Up to 1 in 4 women have interest in pursuing a safe and effective vaginal rejuvenation product if made available. Peach believes its bioelectric and ultrasonic treatment option may be proven out in well controlled studies to be safer and more effective than alternative choices such as laser therapies very popular today.
Major Organ Regeneration – Up to 4 products entering clinical stage of development of 12 in group
>  BladderCell – –  bladder regeneration for incontinence treatment – entering clinical trials in Brazil. The overactive bladder market is expected to reach over $4.5 billion by 2024. We believe our combination bioelectric and biologics product has the potential to offer a better solution to these millions of patients. Over 75% of these patients are women making this a major women’s health initiative issue.
>  OrthoStim – knee regeneration – entering clinical trials in Los Angeles area. The joint inflammation treatment market is expected to exceed $106 billion by 2020. Biological treatments for orthopedic injuries, a sector that was valued at $5 billion in 2015 and is expected to swell to $10.2 billion in 2025. We believe our unique combination of bioelectrics and biologics has the potential to provide more rapid and complete healing of joint pain and orthopedic injuries, diseases and the detrimental effects of aging on bones, tendons, meniscus, cartilage, muscles and joints.
>  EyeCell – – eye regeneration – completed grant supported study at U of Utah in small animals. Now moving to large animal studies. The vision correction and recovery market exceeds $60 billion annually. EyeCell believes its combination bioelectrics and biologics therapies may offer a better treatment option for many patients with reduced or lost vision.
 PancreaCell –  – pancreas regeneration – preparing for large animal studies at University of Miami. Finalist last year in ADA Innovation Awards. The artificial pancreas market is project to reach $400 billion by the end of this decade. PancreaCell believes its bioelectric and biologics therapy for restoring your own natural pancreas may be proven out to be a better option for may instead of an artificial implant. The pancreatitis market exceeds $12 billion annually and PancreaCell may offer a viable treatment choice for these patients as well. Recovery from pancreatic cancer with pancreas regeneration after cancer treatment is another possible application of this technology with a huge unmet need with annual market size exceeding $13 billion.
>  RegenaLung – –  lung regeneration – preparing to enter animal studies. The chronic lung disease and COPD markets are expected to soon exceed $100 billion annually and could be larger with more effective treatment option. RegenaLung believes its combination bioelectric and biologics treatment has the potential to be best choice for many of these patients.
 LiverCell – –  liver regeneration – preparing to enter animal studies in Pittsburgh. The U.S. liver disease treatment market alone is at over $9 billion annually. LiverCell believes its combination bioelectric and biologics treatment has the potential to be the best alternative for patients suffering of liver failure.
>  KidneyCell – – kidney regeneration – preparing to enter animal studies in Pittsburgh. The kidney treatment market exceeds $14 billion annually. KidneyCell believes its combination bioelectric and biologics treatment option has the potential to provide much better results than current treatment options.
>  EarCell – – ear hearing regeneration – searching for research collaborators. Over 360 million people people worldwide suffer of hearing loss. Over 4 million hearing aides were sold last year. No current treatment restores natural hearing reliability and safety. EarCell believes its combination bioelectric and biologics treatment has the potential to revolutionize hearing loss treatment and restore hearing to millions without the need for hearing aides.
 InStim – – bioelectric inflammation management – planning clinical trials in China. Real time read and customized bioelectric inflammation management via anti-inflammatory cytokine expressions. The anti-inflammatory drugs market exceeds $106 billion annually but barely dents the potential total available market. InStim believes its real time bioelectric read and treat technology has the potential to provide superior results compared to currently available therapies.
>  PolypStim – – bioelectric polyp, cyst or fibroid treatment – preparing for animal studies that lead into clinical studies. The globules market for treating polyps, fibroids and cysts exceeds $100 billion annually. PolyStim believes its combination bioelectric and biologics – scan, zap, spray, stimulate treatment option may be a better solution for millions of patients.
>  Wave – – bioelectric endometriosis treatment – preparing for clinical studies in Brazil. Painful endometriosis affects up to 10 to 15% of all women of reproductive age. There is no known cure yet for endometriosis. The market for endometriosis today exceeds $2 billion annually. Wave believes its combination bioelectric and biologics therapy may be proven out to be a best option for millions of women suffering of this disorder.
>  BioLeonhardt Whole Body Regeneration – – whole body regeneration chamber – filing National Science Foundation SBIR grant application. Developing a “womb” for adults. Intended to reduce age by 30 years and extend life by 30 years (unproven early stage development). It is estimated that up to 3 billion people worldwide would choose whole body regeneration if proven to be safe, convenient, affordable and effective. The BioLeonhardt Whole Body Regeneration Chamber is designed to have the patient lie in a oxygenated gelatin bed with bioelectric signals, micro needles and in some severe cases robotic driven bioelectric stimulation and infusion catheters directed directly to organs for more direct regeneration. Regeneration is attempted first with fully non-invasive or minimally invasive infusion means. Regenerative composition capsules are homing guided to organs via temporal interference of crossing two non-invasive electro magnetic frequency signals at a target locations point ie; kidney, liver, brain, heart, pancreas, lungs. The step up to more invasive delivery of regeneration promoting bioelectric signaling sequences and stem cell based mixed compositions is only utilized when absolutely needed. The process starts with a bioelectric scan of the entire body which includes non-invasive technology for early detection of cancers – If cancer is detected the tumors are read and a specific sequences of bioelectric signals are delivered for treatment starting with jamming communication, starving tumor of blood supply and triggering an immune response –
CancerCell – –  bioelectric cancer therapy – entering animal studies at UCLA.  Multiple issued patents and many pending.  Read cancer tumor and custom deliver bioelectric signaling sequence designed to jam communication, trigger immune response, starve blood supply, halt cell division, rupture cancer cells, manage inflammation, re-program cancer cells and after tumor is eradicated regenerate the organ.  Two competitors Novocure and Pulsed Biosciences both published recently successful clinic results with bioelectric therapies for cancer.  They reached $2 billion and $550 million valuations after pilot study results.  Novocure only jams communication.  Pulsed Biosciences slightly triggers a partial immune response. We believe our multi-modality CancerCell approach which is customized based on reading tumors will prove out to provide superior results in upcoming studies. 
QUOTE – “These are forward looking projections. As we are a startup the only thing we can guarantee is that we will miss them over and over again, until we survive our own mistakes” Rachid Sefrioui, Professional Investor, Venture Capitalist @ Finaventures, Entrepreneur
By nature of being extremely short in scope elevator pitches leave out relevant risks and can be misleading in portraying a technology or company to be better than it may appear if a more lengthy and comprehensive presentation is made. The conciseness of the language by nature is slanted to the positive and de-emphasizes risks and obstacles.
These risks include…
1. Startups may not have or secure resources to brings it products to market.
2. None of these startups have tested their products sufficiently enough to make any definitive product or company performance claims.
3. The startups patents pending may not be issued. Patent license agreements may not hold up.
4. All the company agreements, including patent licenses, supply and research agreements are subject to conditions which may not be met or may not have already been met to keep them active and enforceable.
5. The company with a small staff undertaking so many activities is bound to have mistakes in information and outdated information on selected web sites and other documents.
6. Any early stage investment is high risk but these startups are even higher risk since they attempt to take on very large medical problems where other firms with much more substantial resources have failed.
7. No other firm has been highly successful financially in stem cell or bioelectric based organ regeneration. Most of the startups in these accelerators are attempting to do something which has never been done before.
8. Traditionally it costs hundreds of millions of dollars just to bring one of these products to market and many years of development by a focused team of professionals. This accelerator business model attempts to bring up to 30 innovations through first-in-man studies with a substantially smaller staff with dramatically substantially less resources than our traditionally required for even one startup of this type. This in and of itself is and indicator of associated extremely high investment risk.
9. Personnel highlighted as being involved in the projects and startups are nearly all part time and are not compensated most often by cash. Many consultants and advisors listed limit their help to a few hours annually. A number do not have signed agreements in place and are working with the companies in a less formal capacity.
10. Research projects started may not be finished for a variety of reasons.
These elevator pitches do not purport to be all-inclusive or necessarily to contain all the information that a prospective investor may desire in investigating the Company, and may be subject to updating, withdrawal, revision or amendment. No representation or warranty, express or implied, is or will be given by Leonhardt’s Launchpads, the Company, their advisers or any of their respective directors, shareholders, partners or employees as to the accuracy or completeness of the pitches or the information or opinions contained therein.
Any financial projections given are illustrative only and none of the projections or assumptions should be taken as promises on the part of the Company nor should they be taken as implying any indication, assurance or guarantee that those assumptions are correct or exhaustive.
These pitches contain forward-looking statements. These statements relate to, amongst other things, the Company’s future prospects, developments and business strategies. Forward-looking statements are identified by their use of terms and phrases such as “believe”, “could”, “envisage”, “estimate”, “intend”, “may”, “plan”, “will” or the negative of those, variations or comparable expressions, including references to assumptions.
The forward-looking statements in this Pitch are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Company’s actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward looking statements. These forward-looking statements are made only as at the date of the Pitch.
Each recipient of these Pitches must make their own independent assessment of the information provided by the Company and is recommended to seek independent advice on the contents hereof from an authorized person specializing in advising on investments of the kind in question. Neither the Company, Leonhardt’s Launchpads, nor any of their advisers, nor their respective directors, partners, representatives, agents, consultants or employees shall be liable for any direct, indirect or consequential loss or damage suffered by any person relying on statements or omissions from the Pitch and to the maximum extent permitted by law, all conditions, warranties and other terms which might be implied by statute, common law or the law of equity and any such liability are expressly excluded. The Pitch should not be construed as a recommendation to prospective investors by the Company or Leonhardt’s Launchpads, Cal-X Stars Business Accelerator, Inc., or any of their respective officers to invest in the Company, and does not form any commitment by the Company to proceed with an investment. The Company and Leonhardt’s Launchpads, Leonhardt Ventures or Cal-X Stars Business Accelerator, Inc. reserve the right to terminate the procedure at any time and to terminate any discussions and negotiations with any prospective investors at any time and without giving any reason.
Any and all discussions, negotiations and communications, including through any online forums, between any recipient of the Pitches and the Company and their respective directors, shareholders, employees, advisers and/or representatives will remain subject to contract. Any person who invests in the Company at any time must comply with all applicable laws and regulations in force in any jurisdiction in which they acquire, offer or sell shares and must obtain any consent, approval or permission required in respect of any such transaction under the laws and regulations in force in any jurisdiction to which they are subject or in which any such transaction takes place or in which they possess the Pitch. Neither the Company, Leonhardt’s Launchpads, nor any of their respective directors, partners, representatives, agents, consultants or employees shall have any responsibility for any such matters.
The distribution of the Pitches in certain jurisdictions other than California may be restricted by law and therefore persons accessing the Pitch into whose possession the Pitch documents come should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of securities laws of any such jurisdiction. Recipients represent and warrant to the Company and Leonhardt’s Launchpads, that they are able to receive the Pitches without contravention of applicable legal or regulatory restrictions in the jurisdiction in which they reside, conduct business or receive the Pitches, including in particular the requirements of the Act.
The individual startups accept highlighted in this listing of elevator pitches accept responsibility for the information contained in each Pitch. The Pitches are meant to only reflect the most positive and optimistic personal opinion of the company founders and nothing more or less. To the best of the knowledge and belief of the Company (who has taken all reasonable care to ensure that such is the case) the information contained in this Pitch is in accordance with the facts and there are by the extreme brief nature of the few line elevator pitches there are indeed facts the omission of which would affect the validity of such information. This information may be obtained elsewhere such as our private placement memorandum, our annual report or the risk and warnings disclaimers proceeding and following the elevator pitches on this page or on the individual startup web sites. These risks include in brief – patents cited may not protect us, patent license agreements may not hold up, patents pending may not be issued, company lacks resources to complete research, early data is not enough to determine definitively if technology works, all agreements are subject to conditions being met and due to lack of financial resources the likelihood and risk of not meeting such conditions is high, many agreements may not be properly ratified or signed, company is underfunded and understaffed and personnel aboard have diverted attention with other jobs and many projects.
The information contained in the Updates section and the Q&A section and any downloaded documents do not form part of the Pitch and have not been reviewed or approved by Leonhardt’s Launchpads Board of Directors or Legal Counsel. Similarly, any information published outside of the Leonhardt’s Launchpads web sites, including on social media platforms (e.g. Facebook, Twitter) or the Company’s news blog, does not form part of the Pitches. Leonhardt’s Launchpads, Leonhardt Ventures and Cal-X Stars Business Accelerator, Inc. assumes no responsibility for information contained in the Q&A or Updates section, downloads or in any form of media outside the Leonhardt’s Launchpads accelerator and such information should not be deemed an offer or invitation to invest or be relied on to invest.
Potential investors should be aware of the risks associated with an investment in the Company especially at an early stage in its development and should ensure that they have read and understood the Risk Warning on the Leonhardt’s Launchpads, Cal-X Stars Business Accelerator, or Leonhardt’s Launchpads websites before continuing. If any potential investors are in any doubt regarding the contents of any Pitches, they must consult their own professional financial advisers.
Investment in the Company carries substantial risk and may involve special risks that could lead to a loss of all or a substantial amount of such investment. Unless prospective applicants for shares fully understand and accept the nature of the Company and the potential risks inherent in the Company they should not invest in the Company. A prospective investor should consider carefully whether an investment in the Company is suitable for themselves in the light of their personal circumstances, the economic climate and the financial resources available to them. There can be no assurance that the Company’s objectives in respect to any of its funds will be achieved and investment results may vary substantially over time. As such, an investor’s capital may be at risk.
Leonhardt’s Launchpads by Cal-X Stars, 12655 W Jefferson Blvd, Los Angeles, CA 90066
Leonhardt’s Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84115